GLP1R and metabolic dysfunction-associated steatohepatitis: Together, the above studies indicate the potential of GLP1 receptor agonists for concurrent treatment of NASH and ASCVD, which should be confirmed in long-term studies assessing cardiovascular outcomes in patients with NASH.